Simpler Grants.gov #PAR-24-293

NIH Solicits Biologic-Based Drug Discovery for Nervous System Disorders

The National Institutes of Health (NIH) is seeking proposals for the Blueprint Neurotherapeutics Network (BPN) to advance biologic-based drug discovery and development for nervous system disorders. - Government Buyer: - National Institutes of Health (NIH) - Products/Services Requested: - Preclinical discovery and development of biologic-based therapeutic biotechnology products and biologics - Includes proteins, antibodies, peptides, gene-based therapies (oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies) - Collaboration with NIH-funded consultants and contract research organizations for: - Manufacturing and scale-up - Pharmacokinetics - Toxicology - Phase I clinical testing - Unique/Notable Requirements: - Awardee institutions retain intellectual property rights for developed biotherapeutics - Assignment of IP rights from BPN-Biologics contractors to awardees for candidates developed under the program - Open to a wide range of applicants: government entities, educational institutions, nonprofits, and businesses - No specific OEMs or vendors are named; focus is on R&D of new biologic therapies - OEMs: - No specific OEMs identified, as the opportunity is for research and development of novel biologics - Place of Performance: - National Institutes of Health (NIH)

Description

This funding opportunity supports biologic-based therapeutic discovery and development from lead optimization through phase I clinical testing. It includes support for preclinical discovery and development of therapeutic biotechnology products and biologics such as proteins, antibodies, peptides, gene-based therapies, cell therapies, and novel emerging therapies. Applicants collaborate with NIH-funded consultants and may augment projects with NIH contract research organizations specializing in manufacturing, scaling, pharmacokinetics, toxicology, and phase I clinical testing. Awardee institutions retain intellectual property rights and control patent prosecution and licensing negotiations for biotherapeutic candidates developed under this program.

View original listing